RT
The startup has developed a biopharmaceutical platform that creates small molecule inhibitors targeting cancer cell survival mechanisms under stress. This technology aims to enhance treatment options for patients suffering from various forms of cancer by directly disrupting the fundamental processes that allow cancer cells to thrive.
Updated 2 months ago
Funding
$198.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a biopharmaceutical platform that creates small molecule inhibitors targeting cancer cell survival mechanisms under stress. This technology aims to enhance treatment options for patients suffering from various forms of cancer by directly disrupting the fundamental processes that allow cancer cells to thrive.